1. An efficient strategy for digging protein-protein interactions for rational drug design - A case study with HIF-1α/VHL.
- Author
-
Xue X, Kang JB, Yang X, Li N, Chang L, Ji J, Meng XK, Zhang HQ, Zhong Y, Yu SP, Wu WY, Wang XL, Li NG, and Sun SL
- Subjects
- Cell Survival drug effects, Dose-Response Relationship, Drug, HeLa Cells, Humans, Hydroxyproline chemical synthesis, Hydroxyproline chemistry, Hypoxia-Inducible Factor 1, alpha Subunit metabolism, Molecular Dynamics Simulation, Molecular Structure, Protein Binding drug effects, Structure-Activity Relationship, Von Hippel-Lindau Tumor Suppressor Protein metabolism, Drug Design, Hydroxyproline pharmacology, Hypoxia-Inducible Factor 1, alpha Subunit antagonists & inhibitors, Von Hippel-Lindau Tumor Suppressor Protein antagonists & inhibitors
- Abstract
The ubiquitination of the hypoxia-inducible factor-1α (HIF-1α) is mediated by interacting with the von Hippel-Lindau protein (VHL), and is associated with cancer, chronic anemia, and ischemia. VHL, an E3 ligase, has been reported to degrade HIF-1 for decades, however, there are few successful inhibitors currently. Poor understanding of the binding pocket and a lack of in-depth exploration of the interactions between two proteins are the main reasons. Hence, we developed an effective strategy to identify and design new inhibitors for protein-protein interaction targets. The hydroxyproline (Hyp564) of HIF-1α contributed the key interaction between HIF-1α and VHL. In this study, detailed information of the binding pocket were explored by alanine scanning, site-directed mutagenesis and molecular dynamics simulations. Interestingly, we found the interaction(s) between Y565 and H110 played a key role in the binding of VHL/HIF-1α. Based on the interactions, 8 derivates of VH032, 16a-h, were synthesized by introducing various groups bounded to H110. Further assay on protein and cellular level exhibited that 16a-h accessed higher binding affinity to VHL and markable or modest improvement in stabilization of HIF-1α or HIF-1α-OH in HeLa cells. Our work provides a new orientation for the modification or design of VHL/HIF-1α protein-protein interaction inhibitors., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2021 Elsevier Masson SAS. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF